First look at ORY-1001 Phase I/IIa data
Oryzon’s share price soared more than 30% this morning after the abstracts were made available online ahead of the American Society of Hematology (ASH) meeting on 3-6 December. During the poster session at ASH, Oryzon will be presenting the preliminary data from the Phase I/IIa trial with its lead product ORY-1001. In our view, the combination of no negative surprises in the safety profile and the first ever clinical data indicating potential efficacy in a subgroup acute leukemia patients is behind the share price rally today. We expect management to provide comprehensive data at the upcoming ASH meeting on 5 December, when Oryzon will also host an investor meeting. The company has also revealed that multiple sclerosis is now officially included in the development plan of its second product ORY-2001. Our valuation is under review.Oryzon Genomics SA is a Spain-based biopharmaceutical company. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases. The Company's business model focuses on identifying biomarkers that can be translated in new therapeutic targets, as well as on investing in programs, mainly through the development of small molecules for two main indications: cancer and neurodegeneration. The Company develops investigational medicines till proof of concept (POC) phase and then partners the program with pharmaceutical entities, which are able to get the approval from drug agencies to bring these medicines to the patients. It cooperates with Roche. The Company is a subsidiary of Laboratorio Reig Jofre SA.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.